Anti-TNFRSF17 Antibody, clone 2G19 ZooMAb^® Rabbit Monoclonal

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

KLH-conjugated linear peptide corresponding to 20 amino acids from the cytoplasmic domain of human TNFRSF17.

Quality Control Testing

Evaluated by Western Blotting in Raji cell lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected TNFRSF17 in Raji cell lysate.

Tested Applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected TNFRSF17 in BDCM cell lysate.

Affinity Binding Assay: A representative lot of this antibody bound with TNFRSF17 peptide with at least ten thousand-fold (10,000X) higher affinity than with non-specific control peptide.

Immunohistochemistry (Paraffin) Analysis (IHC(P)): A 1:100 dilution from a representative lot detected TNFRSF17 in human spleen tissue sections.

Immunohistochemistry (Paraffin) Analysis (IHC(P)): A 1:100 dilution from a representative lot detected TNFRSF17 in human tonsil tissue sections.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Tumor necrosis factor receptor superfamily member 17 (UniProt: Q02223; also known as B-cell maturation protein, CD269) is encoded by the TNFRSF17 (also known as BCM, BCMA) gene (Gene ID: 608) in human. Tumor necrosis factor receptor superfamily member 17 (TNFRSF17), also known as B-cell maturation antigen (BCMA), is a transmembrane protein belonging to the tumor necrosis factor receptor (TNFR) superfamily. TNFRSF17 is composed of a single-pass type III membrane domain with a cysteine-rich extracellular region that facilitates high-affinity binding with ligands such as APRIL (a proliferation-inducing ligand) and BAFF (B-cell activating factor). The receptor also contains conserved motifs that are critical for signal transduction. BCMA functions as a receptor for these ligands, thereby activating downstream pathways such as NF- B and MAPK8/JNK, which are essential for cell survival, proliferation, and differentiation. The protein is predominantly expressed on mature B lymphocytes and plasma cells, with limited expression in other tissues. TNFRSF17 plays a critical role in humoral immunity, particularly in the survival and function of plasma cells within the bone marrow. Subcellular localization studies indicate that BCMA is found at the plasma membrane and within perinuclear Golgi-like structures. It interacts with adaptor proteins from the TNFR-associated factor (TRAF) family, including TRAF1, TRAF2, and TRAF3, to propagate intracellular signaling cascades. This receptor is also crucial for immunoglobulin A (IgA) responses in mucosal immunity, highlighting its importance in maintaining immune homeostasis. TNFRSF17 has been implicated in various diseases, particularly hematological malignancies such as multiple myeloma, where its expression is significantly upregulated. BCMA serves as a therapeutic target in modern immunotherapies, including chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies, due to its restricted expression on malignant plasma cells. Genetic alterations, such as biallelic deletions or structural mutations within the TNFRSF17 locus, have been identified as mechanisms of resistance to these therapies. Dysregulation of TNFRSF17 signaling is associated with autoimmune disorders, including lupus nephritis and irritable bowel diseases, underscoring its role in immune pathologies. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.

Clone 2G19 is a ZooMAb^® rabbit recombinant monoclonal antibody that detects TNFRSF17. It targets an epitope within 20 amino acids from the cytoplasmic domain.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.